Top

27-03-2024 | Calcimimetic | Original Article

Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials

Authors: Takuya Wakamatsu, Suguru Yamamoto, Koji Matsuo, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa, Junichiro James Kazama

Published in: Journal of Bone and Mineral Metabolism

Abstract

Introduction

This study aimed to assess the effectiveness of calcimimetics in reducing the risk of fractures in dialysis patients with secondary hyperparathyroidism (SHPT).

Material and methods

A comprehensive literature search was conducted using PubMed, Embase, and Cochrane Library for articles published through December 9, 2023. The quality of each trial was evaluated using the Cochrane Collaboration tool. Meta-analysis was performed using a random-effects model, and effect measures across studies were synthesized. The risk ratio (RR) and 95% confidence interval (CI) were used to quantify the risk of fracture.

Results

We identified seven studies involving 6481 dialysis patients with SHPT. The administration of calcimimetics reduced fracture incidence compared to placebo or conventional treatment (RR: 0.50, 95% CI 0.29–0.88, p = 0.02). Calcimimetics demonstrated a low number needed to treat (NNT) to prevent an incident fracture (NNT: 47).

Conclusion

The use of calcimimetics offers a significant benefit in reducing the risk of fractures in patients undergoing dialysis with SHPT.

Available only for authorised users

Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I (2013) Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab 31:315–321. https://doi.org/10.1007/s00774-012-0411-zCrossRefPubMed

Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399. https://doi.org/10.1046/j.1523-1755.2000.00178.xCrossRefPubMed

Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115–1121. https://doi.org/10.1053/ajkd.2000.19812CrossRefPubMed

Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166–173. https://doi.org/10.1038/ki.2013.279CrossRefPubMed

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC, Port FK, Pisoni RL, Robinson BM (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol: CJASN 10:98–109. https://doi.org/10.2215/CJN.12941213CrossRefPubMed

Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T (2013) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Ther Apher Dial: Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jan Soc Dial Ther 17:228. https://doi.org/10.1111/1744-9987.12030CrossRef

Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD (2013) CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol: CJASN 8:2132–2140. https://doi.org/10.2215/CJN.04260413CrossRefPubMedPubMedCentral

Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodriguez-Garcia M, Sanchez JE, Rodriguez-Puyol D, Cannata-Andia JB, group C, (2015) Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol, Dial, Transplant : Off Publ Eur Dial Transplant Assoc - Eur Ren Assoc 30:1542–1551. https://doi.org/10.1093/ndt/gfv099CrossRef

Wakasugi M, Kazama JJ, Kikuchi K, Yasuda K, Wada A, Hamano T, Masakane I, Narita I (2019) Hemodialysis product and hip fracture in hemodialysis patients: a nationwide cohort study in Japan. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Society Dial Ther 23:507–517. https://doi.org/10.1111/1744-9987.12807CrossRef

10.

Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70:1358–1366. https://doi.org/10.1038/sj.ki.5001754CrossRefPubMed

11.

Custodio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhaes AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moyses RM, Jorgetti V (2012) Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol, Dial, Transplant: Off Publ Eur Dial Transplant Assoc – Eur Ren Assoc 27:1437–1445. https://doi.org/10.1093/ndt/gfr447CrossRef

12.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525. https://doi.org/10.1056/NEJMoa031633CrossRefPubMed

13.

Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494. https://doi.org/10.1056/NEJMoa1205624CrossRef

14.

Diaz-Tocados JM, Rodriguez-Ortiz ME, Almaden Y, Pineda C, Martinez-Moreno JM et al (2019) Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int 95:1064–1078. https://doi.org/10.1016/j.kint.2018.12.015CrossRefPubMed

15.

Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T (2021) Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients. Kidney Int Rep 6:2830–2839. https://doi.org/10.1016/j.ekir.2021.08.020CrossRefPubMedPubMedCentral

16.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM (2017) Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 317:156–164. https://doi.org/10.1001/jama.2016.19468CrossRefPubMed

17.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

18.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drueke TB, Evaluation of Cinacalcet HTtLCETI (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the evolve trial. J Am Soc Nephrol 26:1466–1475. https://doi.org/10.1681/ASN.2014040414CrossRefPubMed

19.

Kazama JJ, Koiwa F, Yokoyama K, Fukagawa M, Asano K, Honda D, Akizawa T (2022) First-in-patient phase i/ii study of upacicalcet in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties. Clin Pharmacokinet 61:1271–1284. https://doi.org/10.1007/s40262-022-01139-wCrossRefPubMedPubMedCentral

20.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800. https://doi.org/10.1111/j.1523-1755.2005.00596.xCrossRefPubMed

21.

Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M (2019) An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE 14:e0213774. https://doi.org/10.1371/journal.pone.0213774CrossRefPubMedPubMedCentral

22.

Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T (2023) Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial. Clin J Am Soc Nephrol : CJASN 18:1300–1309. https://doi.org/10.2215/CJN.0000000000000253CrossRefPubMed

23.

Itano Y, Kato S, Tsuboi M, Kasuga H, Tsuruta Y, Sato F, Hishida M, Ishimoto T, Kosugi T, Ando M, Kuwatsuka Y, Maruyama S (2020) A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET trial). Kidney Int Rep 5:2168–2177. https://doi.org/10.1016/j.ekir.2020.09.010CrossRefPubMedPubMedCentral

24.

El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M (2011) Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Soc Dial Ther 15:547–555. https://doi.org/10.1111/j.1744-9987.2011.00994.xCrossRef

25.

Yeung WG, Palmer SC, Strippoli GFM, Talbot B, Shah N, Hawley CM, Toussaint ND, Badve SV (2023) Vitamin D therapy in adults with ckd: a systematic review and meta-analysis. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2023.04.003CrossRefPubMed

26.

Komaba H, Zhao J, Karaboyas A, Yamamoto S, Dasgupta I, Hassan M, Zuo L, Christensson A, Combe C, Robinson BM, Fukagawa M (2023) Active vitamin D use and fractures in hemodialysis patients: results from the international DOPPS. J Bone Miner Res: Off J Am Soc Bone Miner Res 38:1577–1585. https://doi.org/10.1002/jbmr.4913CrossRef

27.

Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18:2401–2407. https://doi.org/10.1681/ASN.2007010022CrossRefPubMed

28.

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ (2015) Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol : CJASN 10:90–97. https://doi.org/10.2215/CJN.03520414CrossRefPubMed

29.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D’Haese PC (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846–856. https://doi.org/10.1038/ki.2014.349CrossRefPubMed

30.

Khairallah P, Cherasard J, Sung J, Agarwal S, Aponte MA, Bucovsky M, Fusaro M, Silberzweig J, Frumkin GN, El Hachem K, Schulman L, McMahon D, Allen MR, Metzger CE, Surowiec RK, Wallace J, Nickolas TL (2023) Changes in bone quality after treatment with etelcalcetide. Clin J Am Soc Nephrol : CJASN. https://doi.org/10.2215/CJN.0000000000000254CrossRefPubMed

31.

Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C Jr, Ominsky MS, Ke HZ, Tomlinson JE, Richards WG (2017) Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone 105:163–172. https://doi.org/10.1016/j.bone.2017.08.026CrossRefPubMed

32.

Al-Dujaili SA, Koh AJ, Dang M, Mi X, Chang W, Ma PX, McCauley LK (2016) Calcium sensing receptor function supports osteoblast survival and acts as a co-factor in pth anabolic actions in bone. J Cell Biochem 117:1556–1567. https://doi.org/10.1002/jcb.25447CrossRefPubMedPubMedCentral

33.

Disease K (2011) Improving global outcomes ckdmbduwg (2017) kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001CrossRef

34.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder (in eng). Ther Apher And Dial: Off Peer-Rev J Int Soc Apher, Jpn Soc Apher, Jpn Soc Dial Ther 17:247–288. https://doi.org/10.1111/1744-9987.12058CrossRef

35.

Harbord RM, Egger M, Sterne JA (2006) A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443–3457. https://doi.org/10.1002/sim.2380CrossRefPubMed

Title: Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials
Authors: Takuya Wakamatsu
Suguru Yamamoto
Koji Matsuo
Masatomo Taniguchi
Takayuki Hamano
Masafumi Fukagawa
Junichiro James Kazama
Publication date: 27-03-2024
Publisher: Springer Nature Singapore
Keywords: Calcimimetic
Cinacalcet
Hyperparathyroidism
Published in: Journal of Bone and Mineral Metabolism
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-024-01500-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com